Cyberonics Inc (CYBX) 69.95 $CYBX
United States Electromedical and Electrotherapeutic Apparatus Market Report 2016 - Analysis And Forecast to 2020
M2 - Mon Jan 25, 9:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/6mvcjq/u_s) has announced the addition of the "U.S. Electromedical And Electrotherapeutic Apparatus Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Electromedical And Electrotherapeutic Apparatus market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Product coverage: - Electromedical equipment (including diagnostic, therapeutic, and patient monitoring equipment), excluding ionizing radiation equipment - Electronic hearing aids, complete units - Electromedical and electrotherapeutic apparatus manufacturing Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - St. Jude Medical - Zimmer Biomet Holdings - Varian Medical Systems - Medtronic - Hologic - Abbott Vascular - Zoll Medical Corporation - Cyberonics - Fujifilm Sonosite - Biomerieux - Masimo Corporation - Starkey Laboratories - Volcano Corporation - Philips Ultrasound - Thoratec Corporation - Nxstage Medical - Danaher Corporation - Abiomed - GE Medical Systems Information Technologies - Natus Medical Incorporated - Conmed Corporation - Pacesetter - Amplifon (usa) - Zimmer - Cynosure - Mindray Ds Usa - Orchid Orthopedic Solutions - Zoll Services - Datex-Ohmeda - Medtronic Minimed - Terumo Cardiovascular Systems Corporation - Nellcor Puritan Bennett Incorporated - Cardiac Pacemakers - Halyard Sales For more information visit http://www.researchandmarkets.com/research/6mvcjq/u_s
ZBH: 129.40 (+1.05), MASI: 59.90 (+0.47), MDT: 87.32 (+0.34), MDSY: 1.30 (-0.08), DHR: 81.19 (-0.25), CYBX: 69.95 (+0.86), BABY: 40.64 (+0.93), VAR: 96.41 (+0.52), VOLC: 17.99 (+0.01), STJ: 78.65 (+0.51), THOR: 63.50 (+0.05), HOLX: 38.51 (+0.05)
Vagus Nerve Stimulators - Pipeline Review, 2015 - Analysis & Technologies
M2 - Mon Dec 21, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/dprxlm/vagus_nerve) has announced the addition of the "Vagus Nerve Stimulators - Pipeline Review, 2015" report to their offering. The Medical Devices sector report, Vagus Nerve Stimulators - Pipeline Review, 2015" provides an overview of Vagus Nerve Stimulators currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. Key Topics Covered: - Extensive coverage of the Vagus Nerve Stimulators under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - Recent developments in the segment / industry Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Vagus Nerve Stimulators under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - BioControl Medical - Boston Scientific Corporation - CerboMed GmbH - Cerebral RX Ltd. - Children's Hospital Boston - Cyberonics, Inc. - DuoCure Ltd. - ElectroCore, LLC - Medical University of South Carolina - MicroTransponder Inc. - Neurostream Technologies G.P. - Setpoint Medical Corporation - Sorin S.p.A. - Trifectas Medical Corp. Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies 5 Vagus Nerve Stimulators Companies and Product Overview 6 Vagus Nerve Stimulators- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/dp...agus_nerve
BSX: 24.26 (-0.07), CYBX: 69.95 (+0.86)
Neuromodulation Devices Global Market - Forecast To 2021 - Low Approval Rate And Cuts In R&D Budget Of CNS Drugs To Drive Neuromodulation Market
M2 - Mon Dec 14, 5:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/7njttk/neuromodulation) has announced the addition of the "Neuromodulation Devices Global Market - Forecast To 2021" report to their offering. According to this report, the global neuromodulation devices market is expected to grow at a double digit CAGR to reach $9.3 billion by 2021. Factors driving the neuromodulation market include, projected increase in patients with chronic pain, neurodegenerative diseases, psychiatric conditions, improvements in technology such as miniaturization, better battery technology, use of bioactive coatings are all contributing for growth of neuromodulation devices market whereas risk of side effects, availability of alternative treatment and high initial cost of implants are the factors hampering the market growth. Advancement of technology with its wide application areas shows that neuromodulation devices market has vast opportunities in the coming years. Neuromodulation devices market is segmented on the basis of technology as internal and external neuromodulation. The internal neuromodulation is again classified into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS) and Other with Gastric Electric Stimulation (GES) and Respiratory Electrical Stimulation (RES)/Phrenic Nerve Stimulation (PNS). Based on the application the neuromodulation devices market is segmented into Chronic Pain, Movement Disorders, Psychiatric Conditions, Gastroenterology & Urology and other applications. Based on end-users the market is segmented into hospitals and private neuromodulation clinics. North America accounts for the highest market share of 56.1% followed by Europe. Steep rise in ageing population, advancement in technology, awareness of people and favourable government policies makes U.S. the leader of neuromodulation devices market. However, Asian countries especially India and China are the fast growing regions with its growing demand for neuromodulation devices. Major players in Neuromodulation devices market include Medtronic (Ireland), Boston Scientific (U.S.), Cyberonics (U.S.), St. Jude Medical (U.S.), Neurometrix, Inc (U.S.), Neuronetics, Inc (U.S.), Nevro Corporation (U.S.), Synapse Biomedical (U.S.), Avery Biomedical (U.S.) and Magstim (U.K.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Neuromodulation Devices Global Market, By Technology 5 Global Neuromodulation Devices Market, By Applications 6 Neuromodulation Devices Global Market, By End-Users 7 Regional Analysis 8 Company Developments 9 Company Profiles - Avery Biomedical - Boston Scientific - Cyberonics - Magstim - Medtronic - Neurometrix Inc - Neuronetics Inc - Nevro Corporation - St. Jude Medical - Synapse Biomedical For more information visit http://www.researchandmarkets.com/research/7n...modulation
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
LivaNova Provides Business Update
GlobeNewswire - Thu Nov 12, 6:00AM CST
LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company"
, a global medical technology company formed by the merger of Sorin S.p.A ("Sorin" , a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. ("Cyberonics" , a medical device company with core expertise in neuromodulation, today provided the sales results for the three and nine months ended September 30, 2015 for Sorin's Cardiac Surgery and Cardiac Rhythm Management ("CRM" business units, and the thirteen and thirty-nine weeks ended September 25, 2015 for Cyberonics' Neuromodulation business unit. These periods will be referred to as the third quarter, or three months ended September 30, 2015, and the nine months ended September 30, 2015, respectively, throughout this press release.
LIVN: 60.95 (+0.74), CYBX: 69.95 (+0.86)
Global Market Study on Neurostimulation Devices 2015: Deep Brain Stimulation Devices to Witness Highest Growth by 2020
M2 - Tue Nov 03, 8:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/tsfgdh/global_market) has announced the addition of the "Global Market Study on Neurostimulation Devices: Deep Brain Stimulation Devices to Witness Highest Growth by 2020" report to their offering. The global neurostimulation devices market is anticipated to grow from an estimated US$ 5,088.9 Mn in 2014 to US$ 10,445.7 Mn by 2020 at a CAGR of 12.7% during the forecast period. The global neurostimulation devices market is witnessing significant growth due to increasing prevalence of chronic pain and rising incidences of neurological diseases. Moreover, rising awareness about various neurological diseases, growing geriatric population, and increasing investments in research and development of innovative neurostimulation devices are the other factors driving the market. However, availability of alternative treatment therapies for neurological diseases and side-effects of neurostimulation therapy inhibits the growth of the market. North America is the largest market, while Asia Pacific represents the fastest-growing market for neurostimulation devices. Spinal cord stimulation (SCS) represents the largest segment, while deep brain stimulation (DBS) is the fastest-growing implantable neurostimulation device sub-segment in the market. Transcutaneous electrical nerve stimulation (TENS) is the largest and fastest-growing external device sub-segment in the market. In terms of application, pain management represents the largest and fastest-growing application segment in the neurostimulation devices market. The neurostimulation devices market in North America is anticipated to grow from an estimated US$ 2,449.9 Mn in 2014 to US$ 4,892.9 Mn by 2020 at a CAGR of 12.2% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5Global Market Size and Forecast Chapter 6 Market Size and Forecast, by Device Type Chapter 7 Market Size and Forecast, by Implantable Devices Chapter 8 Market Size and Forecast, by External Devices Chapter 9 Market Size and Forecast, by Application Chapter 10 Market Size and Forecast, by Geography Chapter 11 Competitive Scenario Chapter 12 Company Profiles - Boston Scientific Corporation - Cochlear, Ltd. - Cyberonics, Inc. - MED-EL - Medtronic plc - NDI Medical, LLC - NeuroPace, Inc. - NeuroSigma, Inc. - St. Jude Medical, Inc. For more information visit http://www.researchandmarkets.com/research/ts...bal_market
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NSIG: (), CYBX: 69.95 (+0.86)
U.S. Neurostimulation Devices Market 2014-2019 - Market Has Reached Nearly $2.3 Billion in 2014
M2 - Thu Oct 22, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfs5b7/u_s) has announced the addition of the "U.S. Neurostimulation Devices Market" report to their offering. Implantable neurostimulation systems typically consist of three implantable components (the extension, lead, and power source) and two external components (the control magnet and a handheld programmer). The extension is used to connect the lead to the power source, and the lead is used to deliver the electrical stimulation to the targeted nerve(s). For the purposes of this report, the total U.S. market for implantable neurostimulation devices includes sales derived from systems for 8 therapy segments, including the 5 core, established areas of deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), as well as neural prostheses (cochlear and recently launched retinal implants) and newly FDA-approved Vagal Blocking (VBLOC) therapy, for the treatment of obesity. The large and burgeoning market for implantable neurostimulation devices in the U.S. has reached nearly $2.3 billion in 2014. Despite the lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of startups and leading medical device companies. The market is expected to experience high single-digit growth over the next half-decade, with many industry experts expecting its value to rival the multibillion-dollar markets for implantable defibrillators and coronary stents. A major reason for such optimism is not only the products' clinical and commercial success thus far, but also the need for more effective treatments for the large population of patients who suffer from debilitating, chronic, incurable conditions that require the long-term management of symptoms. This dynamic, new report includes analyses of dozens of selected products, current/forecast markets (from 2014-2019), disease prevalence, competitors, market share by supplier, and opportunities in the U.S. Neurostimulation Devices Market. Specifically, this report covers leading and emerging implantable neurostimulation devices and next-generation technologies, as well as increasingly competitive less invasive or nonsurgical therapies, such as transcutaneous electrical nerve stimulation (TENS), peripheral nerve stimulation (PNS), transcutaneous magnetic stimulation (TMS), and external trigeminal nerve stimulation (eTNS). Key Topics Covered: Executive Summary 1. Neurostimulation Technologies Overview 1.1 Implantable Neurostimulators 1.2 Noninvasive Peripheral Nerve Stimulation 1.3 Transcutaneous Electrical Nerve Stimulation 1.4 Closed-Loop Stimulation 1.5 Hypoglossal Nerve Stimulation 1.6 Transcutaneous Magnetic Stimulation 1.7 External Trigeminal Nerve Stimulation 2. Neurostimulation Devices 3. Implantable Neurostimulation Devices Market 3.1 Market Forecast 3.2 Competitive Analysis 3.3 Emerging Neurostimulation Technologies Companies Mentioned - Advanced Bionics AG/Sonova Group - Autonomic Technologies, Inc. - Beijing Pins Medical Co., Ltd - Bioness, Inc. - Boston Scientific - Cerbomed GmbH - CerebralRx/BioControl Medical - Cochlear, Ltd. - Cyberonics/Sorin Group - Electrical Geodesics, Inc. - EndoStim - ImThera Medical - Inspire Medical Systems - MED-EL - Mainstay Medical - Medtronic plc - NeuroMetrix - NeuroPace - NeuroSigma - NeuroVista/Cyberonics - Neuros Medical - Nevro Corp. - SPR Therapeutics - Saluda Medical - St. Jude Medical - Stimwave Technologies, Inc. - Synapse Biomedical For more information visit http://www.researchandmarkets.com/research/rfs5b7/u_s
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
Varian: ProBeam Compact Launched, FDA Nod for New Eclipse
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 12:00PM CDT
Varian Medical Systems Inc. (VAR) is riding high on the back of its innovative product pipeline, regulatory wins and frequent product launches.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), VAR: 96.41 (+0.52), CYBX: 69.95 (+0.86)
AngioDynamics Expands in Asia with NanoKnife Approvals
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 11:40AM CDT
AngioDynamics Inc. (ANGO) continues to expand its international footprint through product approvals gained in different countries.
MASI: 59.90 (+0.47), MZOR: 22.23 (+0.37), ANGO: 16.75 (+0.17), CYBX: 69.95 (+0.86)
Exactech Third-Quarter Estimates Reflect Low Global Sales
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 3:05PM CDT
Exactech Inc. (EXAC) recently announced preliminary third-quarter 2015 estimates.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CYBX: 69.95 (+0.86)
LivaNova Begins Trading on NASDAQ and London Stock Exchange
Thomson Reuters ONE - Mon Oct 19, 9:52AM CDT
LONDON, Oct. 19, 2015 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company" today announces the successful completion of the cross-border merger of Sorin S.p.A. and Cyberonics, Inc., creating a new premier medical technology company. Sorin and Cyberonics announced on February 26, 2015 that the boards of directors of both companies unanimously approved a combination of the companies (the "Transaction" under a newly formed holding company organized under the laws of England and Wales, LivaNova PLC ("LivaNova" . The Transaction was overwhelmingly approved by Sorin shareholders on May 26, 2015 and by Cyberonics shareholders on September 22, 2015.
LIVN: 60.95 (+0.74), CYBX: 69.95 (+0.86)
Cyberonics Rises 1.24% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 16, 4:12PM CDT
Cyberonics (NASDAQ:CYBX) traded in a range yesterday that spanned from a low of $68.66 to a high of $70.25. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $69.21 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYBX: 69.95 (+0.86)
Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 3:20PM CDT
Shares of DexCom Inc. (DXCM) surged 19.4% ($13.70) to close at $84.35 on Oct 15, after the company announced an encouraging revenue forecast for the third quarter of 2015.
MASI: 59.90 (+0.47), DXCM: 92.09 (+0.38), MZOR: 22.23 (+0.37), CYBX: 69.95 (+0.86)
Exactech's Acapella One System Launch Widens Spine Suite
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 12:40PM CDT
Exactech Inc. (EXAC) recently unveiled a new Acapella One Cervical Spacer System at the North American Spine Society (NASS) Annual Meeting being held in Chicago, IL.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CYBX: 69.95 (+0.86)
HeartWare Updates on MVAD Trial Enrollment, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 1:25PM CDT
HeartWare (HTWR) disclosed in an 8K filing that it may not resume patient enrollment for the MVAD (miniaturized ventricular assist device) CE Mark clinical trial in November, as was expected earlier.
MASI: 59.90 (+0.47), STJ: 78.65 (+0.51), HTWR: 58.20 (+0.22), CYBX: 69.95 (+0.86)
Cepheid Posts Weak Q3 Preliminary Results, Shares Tank 14%
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 1:10PM CDT
Cepheid (CPHD) expects to deliver net loss per share of 32 cents in the third quarter, wider than the company's expected loss of 28???30 cents per share.
KOOL: 4.10 (-0.07), EDAP: 2.89 (-0.03), CPHD: 34.42 (+0.16), CYBX: 69.95 (+0.86)
Cyberonics-Sorin Appoint LivaNova Members Ahead of Merger
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:30PM CDT
Cyberonics, Inc. (CYBX) and Sorin S.p.A. jointly announced the two remaining designees to the Board of Directors of LivaNova.
MASI: 59.90 (+0.47), OPK: 9.33 (+0.04), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
LivaNova Announces Publication of Prospectus
GlobeNewswire - Mon Oct 12, 8:32AM CDT
THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR A PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF THE SHARES OF LIVANOVA PLC. ANY DECISION TO PURCHASE OR OTHERWISE ACQUIRE, SELL OR DISPOSE OF ANY SHARES OF LIVANOVA PLC MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE IN THE PROSPECTUS ONCE PUBLISHED.
CYBX: 69.95 (+0.86)
Pacific Biosciences (PACB) Jumps: Stock Moves 7.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 7:00AM CDT
Pacific Biosciences (PACB) was a big mover last session, with shares rising over 7% on the day.
PACB: 8.28 (-0.02), CYBX: 69.95 (+0.86)
WaferGen Projects Record High Q3 Revenues; Shares Rally
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 12:00PM CDT
Shares of WaferGen Bio-systems Inc. (WGBS) rallied a significant 47.4% (72 cents) to $2.24 on Oct 8 following encouraging third-quarter preliminary revenue announcement.
MASI: 59.90 (+0.47), MZOR: 22.23 (+0.37), WGBS: 0.83 (-0.01), CYBX: 69.95 (+0.86)
United States Electromedical and Electrotherapeutic Apparatus Market Report 2016 - Analysis And Forecast to 2020
M2 - Mon Jan 25, 9:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/6mvcjq/u_s) has announced the addition of the "U.S. Electromedical And Electrotherapeutic Apparatus Market - Analysis And Forecast to 2020" report to their offering. The report provides an in-depth analysis of the U.S. Electromedical And Electrotherapeutic Apparatus market. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. In addition, the report contains insightful information about the industry, including industry life cycle, business locations, productivity, employment and many other crucial aspects. The Company Profiles section contains relevant data on the major players in the industry. Product coverage: - Electromedical equipment (including diagnostic, therapeutic, and patient monitoring equipment), excluding ionizing radiation equipment - Electronic hearing aids, complete units - Electromedical and electrotherapeutic apparatus manufacturing Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market Overview 4. Domestic Production 5. Imports 6. Exports 7. Competitive Landscape 8. Company Profiles - St. Jude Medical - Zimmer Biomet Holdings - Varian Medical Systems - Medtronic - Hologic - Abbott Vascular - Zoll Medical Corporation - Cyberonics - Fujifilm Sonosite - Biomerieux - Masimo Corporation - Starkey Laboratories - Volcano Corporation - Philips Ultrasound - Thoratec Corporation - Nxstage Medical - Danaher Corporation - Abiomed - GE Medical Systems Information Technologies - Natus Medical Incorporated - Conmed Corporation - Pacesetter - Amplifon (usa) - Zimmer - Cynosure - Mindray Ds Usa - Orchid Orthopedic Solutions - Zoll Services - Datex-Ohmeda - Medtronic Minimed - Terumo Cardiovascular Systems Corporation - Nellcor Puritan Bennett Incorporated - Cardiac Pacemakers - Halyard Sales For more information visit http://www.researchandmarkets.com/research/6mvcjq/u_s
ZBH: 129.40 (+1.05), MASI: 59.90 (+0.47), MDT: 87.32 (+0.34), MDSY: 1.30 (-0.08), DHR: 81.19 (-0.25), CYBX: 69.95 (+0.86), BABY: 40.64 (+0.93), VAR: 96.41 (+0.52), VOLC: 17.99 (+0.01), STJ: 78.65 (+0.51), THOR: 63.50 (+0.05), HOLX: 38.51 (+0.05)
Vagus Nerve Stimulators - Pipeline Review, 2015 - Analysis & Technologies
M2 - Mon Dec 21, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/dprxlm/vagus_nerve) has announced the addition of the "Vagus Nerve Stimulators - Pipeline Review, 2015" report to their offering. The Medical Devices sector report, Vagus Nerve Stimulators - Pipeline Review, 2015" provides an overview of Vagus Nerve Stimulators currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. Key Topics Covered: - Extensive coverage of the Vagus Nerve Stimulators under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - Recent developments in the segment / industry Benefits of this Report: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Vagus Nerve Stimulators under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline Companies Mentioned: - BioControl Medical - Boston Scientific Corporation - CerboMed GmbH - Cerebral RX Ltd. - Children's Hospital Boston - Cyberonics, Inc. - DuoCure Ltd. - ElectroCore, LLC - Medical University of South Carolina - MicroTransponder Inc. - Neurostream Technologies G.P. - Setpoint Medical Corporation - Sorin S.p.A. - Trifectas Medical Corp. Report Structure: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Products under Development 4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies 5 Vagus Nerve Stimulators Companies and Product Overview 6 Vagus Nerve Stimulators- Recent Developments 7 Appendix For more information visit http://www.researchandmarkets.com/research/dp...agus_nerve
BSX: 24.26 (-0.07), CYBX: 69.95 (+0.86)
Neuromodulation Devices Global Market - Forecast To 2021 - Low Approval Rate And Cuts In R&D Budget Of CNS Drugs To Drive Neuromodulation Market
M2 - Mon Dec 14, 5:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/7njttk/neuromodulation) has announced the addition of the "Neuromodulation Devices Global Market - Forecast To 2021" report to their offering. According to this report, the global neuromodulation devices market is expected to grow at a double digit CAGR to reach $9.3 billion by 2021. Factors driving the neuromodulation market include, projected increase in patients with chronic pain, neurodegenerative diseases, psychiatric conditions, improvements in technology such as miniaturization, better battery technology, use of bioactive coatings are all contributing for growth of neuromodulation devices market whereas risk of side effects, availability of alternative treatment and high initial cost of implants are the factors hampering the market growth. Advancement of technology with its wide application areas shows that neuromodulation devices market has vast opportunities in the coming years. Neuromodulation devices market is segmented on the basis of technology as internal and external neuromodulation. The internal neuromodulation is again classified into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Sacral Nerve Stimulation (SNS) and Other with Gastric Electric Stimulation (GES) and Respiratory Electrical Stimulation (RES)/Phrenic Nerve Stimulation (PNS). Based on the application the neuromodulation devices market is segmented into Chronic Pain, Movement Disorders, Psychiatric Conditions, Gastroenterology & Urology and other applications. Based on end-users the market is segmented into hospitals and private neuromodulation clinics. North America accounts for the highest market share of 56.1% followed by Europe. Steep rise in ageing population, advancement in technology, awareness of people and favourable government policies makes U.S. the leader of neuromodulation devices market. However, Asian countries especially India and China are the fast growing regions with its growing demand for neuromodulation devices. Major players in Neuromodulation devices market include Medtronic (Ireland), Boston Scientific (U.S.), Cyberonics (U.S.), St. Jude Medical (U.S.), Neurometrix, Inc (U.S.), Neuronetics, Inc (U.S.), Nevro Corporation (U.S.), Synapse Biomedical (U.S.), Avery Biomedical (U.S.) and Magstim (U.K.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Neuromodulation Devices Global Market, By Technology 5 Global Neuromodulation Devices Market, By Applications 6 Neuromodulation Devices Global Market, By End-Users 7 Regional Analysis 8 Company Developments 9 Company Profiles - Avery Biomedical - Boston Scientific - Cyberonics - Magstim - Medtronic - Neurometrix Inc - Neuronetics Inc - Nevro Corporation - St. Jude Medical - Synapse Biomedical For more information visit http://www.researchandmarkets.com/research/7n...modulation
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
LivaNova Provides Business Update
GlobeNewswire - Thu Nov 12, 6:00AM CST
LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company"
, a global medical technology company formed by the merger of Sorin S.p.A ("Sorin" , a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. ("Cyberonics" , a medical device company with core expertise in neuromodulation, today provided the sales results for the three and nine months ended September 30, 2015 for Sorin's Cardiac Surgery and Cardiac Rhythm Management ("CRM" business units, and the thirteen and thirty-nine weeks ended September 25, 2015 for Cyberonics' Neuromodulation business unit. These periods will be referred to as the third quarter, or three months ended September 30, 2015, and the nine months ended September 30, 2015, respectively, throughout this press release. LIVN: 60.95 (+0.74), CYBX: 69.95 (+0.86)
Global Market Study on Neurostimulation Devices 2015: Deep Brain Stimulation Devices to Witness Highest Growth by 2020
M2 - Tue Nov 03, 8:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/tsfgdh/global_market) has announced the addition of the "Global Market Study on Neurostimulation Devices: Deep Brain Stimulation Devices to Witness Highest Growth by 2020" report to their offering. The global neurostimulation devices market is anticipated to grow from an estimated US$ 5,088.9 Mn in 2014 to US$ 10,445.7 Mn by 2020 at a CAGR of 12.7% during the forecast period. The global neurostimulation devices market is witnessing significant growth due to increasing prevalence of chronic pain and rising incidences of neurological diseases. Moreover, rising awareness about various neurological diseases, growing geriatric population, and increasing investments in research and development of innovative neurostimulation devices are the other factors driving the market. However, availability of alternative treatment therapies for neurological diseases and side-effects of neurostimulation therapy inhibits the growth of the market. North America is the largest market, while Asia Pacific represents the fastest-growing market for neurostimulation devices. Spinal cord stimulation (SCS) represents the largest segment, while deep brain stimulation (DBS) is the fastest-growing implantable neurostimulation device sub-segment in the market. Transcutaneous electrical nerve stimulation (TENS) is the largest and fastest-growing external device sub-segment in the market. In terms of application, pain management represents the largest and fastest-growing application segment in the neurostimulation devices market. The neurostimulation devices market in North America is anticipated to grow from an estimated US$ 2,449.9 Mn in 2014 to US$ 4,892.9 Mn by 2020 at a CAGR of 12.2% during the forecast period. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5Global Market Size and Forecast Chapter 6 Market Size and Forecast, by Device Type Chapter 7 Market Size and Forecast, by Implantable Devices Chapter 8 Market Size and Forecast, by External Devices Chapter 9 Market Size and Forecast, by Application Chapter 10 Market Size and Forecast, by Geography Chapter 11 Competitive Scenario Chapter 12 Company Profiles - Boston Scientific Corporation - Cochlear, Ltd. - Cyberonics, Inc. - MED-EL - Medtronic plc - NDI Medical, LLC - NeuroPace, Inc. - NeuroSigma, Inc. - St. Jude Medical, Inc. For more information visit http://www.researchandmarkets.com/research/ts...bal_market
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NSIG: (), CYBX: 69.95 (+0.86)
U.S. Neurostimulation Devices Market 2014-2019 - Market Has Reached Nearly $2.3 Billion in 2014
M2 - Thu Oct 22, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfs5b7/u_s) has announced the addition of the "U.S. Neurostimulation Devices Market" report to their offering. Implantable neurostimulation systems typically consist of three implantable components (the extension, lead, and power source) and two external components (the control magnet and a handheld programmer). The extension is used to connect the lead to the power source, and the lead is used to deliver the electrical stimulation to the targeted nerve(s). For the purposes of this report, the total U.S. market for implantable neurostimulation devices includes sales derived from systems for 8 therapy segments, including the 5 core, established areas of deep brain stimulation (DBS), gastric nerve stimulation (GNS), spinal cord stimulation (SCS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), as well as neural prostheses (cochlear and recently launched retinal implants) and newly FDA-approved Vagal Blocking (VBLOC) therapy, for the treatment of obesity. The large and burgeoning market for implantable neurostimulation devices in the U.S. has reached nearly $2.3 billion in 2014. Despite the lingering economic uncertainty and financial constraints that have affected many other medical device markets, this market is undergoing significant technological advancement due to heavy R&D and investment efforts by dozens of startups and leading medical device companies. The market is expected to experience high single-digit growth over the next half-decade, with many industry experts expecting its value to rival the multibillion-dollar markets for implantable defibrillators and coronary stents. A major reason for such optimism is not only the products' clinical and commercial success thus far, but also the need for more effective treatments for the large population of patients who suffer from debilitating, chronic, incurable conditions that require the long-term management of symptoms. This dynamic, new report includes analyses of dozens of selected products, current/forecast markets (from 2014-2019), disease prevalence, competitors, market share by supplier, and opportunities in the U.S. Neurostimulation Devices Market. Specifically, this report covers leading and emerging implantable neurostimulation devices and next-generation technologies, as well as increasingly competitive less invasive or nonsurgical therapies, such as transcutaneous electrical nerve stimulation (TENS), peripheral nerve stimulation (PNS), transcutaneous magnetic stimulation (TMS), and external trigeminal nerve stimulation (eTNS). Key Topics Covered: Executive Summary 1. Neurostimulation Technologies Overview 1.1 Implantable Neurostimulators 1.2 Noninvasive Peripheral Nerve Stimulation 1.3 Transcutaneous Electrical Nerve Stimulation 1.4 Closed-Loop Stimulation 1.5 Hypoglossal Nerve Stimulation 1.6 Transcutaneous Magnetic Stimulation 1.7 External Trigeminal Nerve Stimulation 2. Neurostimulation Devices 3. Implantable Neurostimulation Devices Market 3.1 Market Forecast 3.2 Competitive Analysis 3.3 Emerging Neurostimulation Technologies Companies Mentioned - Advanced Bionics AG/Sonova Group - Autonomic Technologies, Inc. - Beijing Pins Medical Co., Ltd - Bioness, Inc. - Boston Scientific - Cerbomed GmbH - CerebralRx/BioControl Medical - Cochlear, Ltd. - Cyberonics/Sorin Group - Electrical Geodesics, Inc. - EndoStim - ImThera Medical - Inspire Medical Systems - MED-EL - Mainstay Medical - Medtronic plc - NeuroMetrix - NeuroPace - NeuroSigma - NeuroVista/Cyberonics - Neuros Medical - Nevro Corp. - SPR Therapeutics - Saluda Medical - St. Jude Medical - Stimwave Technologies, Inc. - Synapse Biomedical For more information visit http://www.researchandmarkets.com/research/rfs5b7/u_s
BSX: 24.26 (-0.07), MDT: 87.32 (+0.34), STJ: 78.65 (+0.51), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
Varian: ProBeam Compact Launched, FDA Nod for New Eclipse
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 12:00PM CDT
Varian Medical Systems Inc. (VAR) is riding high on the back of its innovative product pipeline, regulatory wins and frequent product launches.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), VAR: 96.41 (+0.52), CYBX: 69.95 (+0.86)
AngioDynamics Expands in Asia with NanoKnife Approvals
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 11:40AM CDT
AngioDynamics Inc. (ANGO) continues to expand its international footprint through product approvals gained in different countries.
MASI: 59.90 (+0.47), MZOR: 22.23 (+0.37), ANGO: 16.75 (+0.17), CYBX: 69.95 (+0.86)
Exactech Third-Quarter Estimates Reflect Low Global Sales
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 3:05PM CDT
Exactech Inc. (EXAC) recently announced preliminary third-quarter 2015 estimates.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CYBX: 69.95 (+0.86)
LivaNova Begins Trading on NASDAQ and London Stock Exchange
Thomson Reuters ONE - Mon Oct 19, 9:52AM CDT
LONDON, Oct. 19, 2015 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company"
today announces the successful completion of the cross-border merger of Sorin S.p.A. and Cyberonics, Inc., creating a new premier medical technology company. Sorin and Cyberonics announced on February 26, 2015 that the boards of directors of both companies unanimously approved a combination of the companies (the "Transaction" under a newly formed holding company organized under the laws of England and Wales, LivaNova PLC ("LivaNova" . The Transaction was overwhelmingly approved by Sorin shareholders on May 26, 2015 and by Cyberonics shareholders on September 22, 2015. LIVN: 60.95 (+0.74), CYBX: 69.95 (+0.86)
Cyberonics Rises 1.24% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 16, 4:12PM CDT
Cyberonics (NASDAQ:CYBX) traded in a range yesterday that spanned from a low of $68.66 to a high of $70.25. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $69.21 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYBX: 69.95 (+0.86)
Dexcom's Q3 Revenue Forecast Impressive, Stock Rallies
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 3:20PM CDT
Shares of DexCom Inc. (DXCM) surged 19.4% ($13.70) to close at $84.35 on Oct 15, after the company announced an encouraging revenue forecast for the third quarter of 2015.
MASI: 59.90 (+0.47), DXCM: 92.09 (+0.38), MZOR: 22.23 (+0.37), CYBX: 69.95 (+0.86)
Exactech's Acapella One System Launch Widens Spine Suite
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 12:40PM CDT
Exactech Inc. (EXAC) recently unveiled a new Acapella One Cervical Spacer System at the North American Spine Society (NASS) Annual Meeting being held in Chicago, IL.
KOOL: 4.10 (-0.07), MASI: 59.90 (+0.47), EXAC: 27.90 (+0.10), CYBX: 69.95 (+0.86)
HeartWare Updates on MVAD Trial Enrollment, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 1:25PM CDT
HeartWare (HTWR) disclosed in an 8K filing that it may not resume patient enrollment for the MVAD (miniaturized ventricular assist device) CE Mark clinical trial in November, as was expected earlier.
MASI: 59.90 (+0.47), STJ: 78.65 (+0.51), HTWR: 58.20 (+0.22), CYBX: 69.95 (+0.86)
Cepheid Posts Weak Q3 Preliminary Results, Shares Tank 14%
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 1:10PM CDT
Cepheid (CPHD) expects to deliver net loss per share of 32 cents in the third quarter, wider than the company's expected loss of 28???30 cents per share.
KOOL: 4.10 (-0.07), EDAP: 2.89 (-0.03), CPHD: 34.42 (+0.16), CYBX: 69.95 (+0.86)
Cyberonics-Sorin Appoint LivaNova Members Ahead of Merger
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:30PM CDT
Cyberonics, Inc. (CYBX) and Sorin S.p.A. jointly announced the two remaining designees to the Board of Directors of LivaNova.
MASI: 59.90 (+0.47), OPK: 9.33 (+0.04), NVRO: 95.91 (-0.11), CYBX: 69.95 (+0.86)
LivaNova Announces Publication of Prospectus
GlobeNewswire - Mon Oct 12, 8:32AM CDT
THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR A PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF THE SHARES OF LIVANOVA PLC. ANY DECISION TO PURCHASE OR OTHERWISE ACQUIRE, SELL OR DISPOSE OF ANY SHARES OF LIVANOVA PLC MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE IN THE PROSPECTUS ONCE PUBLISHED.
CYBX: 69.95 (+0.86)
Pacific Biosciences (PACB) Jumps: Stock Moves 7.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 7:00AM CDT
Pacific Biosciences (PACB) was a big mover last session, with shares rising over 7% on the day.
PACB: 8.28 (-0.02), CYBX: 69.95 (+0.86)
WaferGen Projects Record High Q3 Revenues; Shares Rally
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 12:00PM CDT
Shares of WaferGen Bio-systems Inc. (WGBS) rallied a significant 47.4% (72 cents) to $2.24 on Oct 8 following encouraging third-quarter preliminary revenue announcement.
MASI: 59.90 (+0.47), MZOR: 22.23 (+0.37), WGBS: 0.83 (-0.01), CYBX: 69.95 (+0.86)
